Impact of amphotericin B on the cytochrome P450 system in HIV-infected patients

European Journal of Medical Research

Volumn 9, Issue 2, 2004, Pages 51-54

  Brockmeyer, Norbert H ^a   Gambichler, T ^a   Bader, A ^a   Kreuter, A ^a   Kurowski, M ^b   Sander, P ^a   Altmeyer, P ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Vivantes Klin Auguste Viktoria K   (Germany)

Author keywords

Amphotericin B; Cytochrome P450; HIV

Indexed keywords

17 HYDROXYCORTICOSTEROID; 6 BETA-HYDROXYCORTISOL; 6BETA HYDROXYHYDROCORTISONE; AMPHOTERICIN B; ANTIINFECTIVE AGENT; CYTOCHROME P450; DRUG DERIVATIVE; HYDROCORTISONE; PHENAZONE;

AIDS RELATED COMPLEX; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; ESOPHAGITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE DEFICIENCY; METABOLISM; MICROBIOLOGY; URINE;

17-HYDROXYCORTICOSTEROIDS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIPYRINE; CANDIDIASIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ESOPHAGITIS; HUMANS; HYDROCORTISONE; IMMUNOCOMPROMISED HOST;

EID: 5444240427     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal, candidiasis in HIV/AIDS patients. HIV Clin Trials 2000;1: 47-59
2. Albengres E, Le Louet H, Tillemann JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18: 83-97
3. Osaka K, Ritov VB, Bernardo JF, Branch RA, Kagan VE. Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob Agents Chemother 1997;41: 743-747
4. van Etten EW, Chander HR, Snjiders SV, Bakker-Woudenberg IA. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans. J Antimicrob Chemother 1995;36: 961-974
5. Geata GB, Utili R, Adilnolfi E, Tripodi MF, Esposito V. Effects of amphothericine B on the excretory function and the colloid clearance capacity of the perfused rat liver. J Hepatol 1989;8: 344-350
6. Heidemann HT, Holzlöhner U, Heydemann J, Freitag T, Inselmann G. Effect of amphothericin B on hepatic cytochrome P-450 and glucose-6-phosphatase in the rat. J Hepatol 1992;14: 300-304
7. Inselmann G, Voss V, Kunigk F, Heidemann HT. Influence of amphothericin B treatment duration of hepatic microsomal enzyme function in rats. Pharmacology 1997;55: 87-94
8. Inselmann G, Volkmann A, Heidemann HT. Comparison of the effects of liposomal amphothericin B and conventional amphothericin B on propafenone metabolism and hepatic cytochrome P-450 in rats. Antimicrob Agents Chemother 2000; 44: 131-133
9. Lin JH, Chen IW, King J. Dose-dependent toxicokinetics of L-689,502, a potent human immunodeficiency virus protease inhibitor, in rats and dogs. J Pharmacol Exp Ther 1992;263: 105-11
10. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997 (25): 256-66
11. Eichelbaum M, Spannbrucker N. Rapid and sensitive method for the determination of antipyrine in biological fluids by high-performance liquid chromatography. J Chrom 140: 288-292
12. Park BK, Knitteringliam NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996; 41: 477-491
13. Cribb AE, Renton KW. Dissociation of xanthine oxidase induction and cytochrom P450 depression during interferon inducing in the rat. Biochem Pharmacol 1993; 46: 2114-2117
14. Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M. Pharmacokinetic interaction of Fluconazole and Zidovudine in HIV - positive patients. Eur J Med Res 1997;2: 377-383
15. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18: 83-97
16. Sahai J, Gallicano K, Pakuts A, Cameron W. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodefiency virus. J Infect Dis 1994;169: 1103-1107
17. Van den Bossche H, Willemsens G, Janssons PA. Cytochrome-P450-dependent metabolism of retinoic acid in rat skin microsomes: inhibition by ketoconazole. Skin Pharmacol 1988; 3: 176-185
18. Inselmann G, Volkmann A, Heidemann HT. Comparison of the effects of liposomal amphothericin B and conventional amphothericin B on propafenone metabolism and hepatic cytochrome P-450 in rats. Antimicrob Agents Chemother 2000;44: 131-133
19. Abajo FJ, Carcas AJ. Amphothericin B hepatotoxicity. Br Med J 1985;293: 1243
20. Massa T, Sinha DP, Frantz JD, et al. Subchronic toxicity studies of N-D-ornithyl amphothericin B methyl ester in dogs and rats. Fundam Appl Toxicol 1985;5: 737-753
21. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identification for the cytochrom P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996;59: 613-623
22. Wietzholtz H, Zysset T, Kreiten K, Kohl D, Buchsel R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;36: 401-406